LONG-TERM HEALTH HAZARD ASSESSMENT
The problem of long-term health hazard identification
Almost for a century, long-term health hazard has been assessed by using testing animals.
For the developers of new materials and drugs the associated testing time scale of months or even years, on which they can be informed on the potential material-or drug-related long-term hazard, strongly demotivates broader developments towards safer materials.
Unfortunately, even for many new NAMs approaches that rely on the mimicking of a tissue or even organism complexity, the very same “time” problem remains unsolved.
IN FINITE SOLUTION TO THE TIME PROBLEM
In finite technology provides a platform of solutions, a complex NAMs methodology to replace whole family of testing guidelines (such as OECD TGs) delivering fast assessment for entire disease evolution not only the selected time points.
Within the scope of OECD Test Guidelines (TGs), a disease is perceived as a single state in time. Because every time point has to be addressed via its own TG, official long-term health hazard assessment is very slow and costly.
In finite platform enables a disease to be perceived as inseparable time evolution with a disease state at the selected time always evolving from states at preceding times.
Knowing one means know them all.
No animals are required, but complex monitoring during in vitro experiment coupled to an automated translation into MoA, creating a digital twin of early disease evolution.
Because a digital twin of a disease represents a disease model, In finite platform can be used for discovery of Mode-of-Action of drugs or therapeutics in general, for identification of on- and off-targets, for drug repurposing, and, because disease evolution can also be predicted, for optimization of therapeutics delivery (dosing and time patterns) as well.